Response to trastuzumab by HER2 expressing breast tumour xenografts is accompanied by decreased Hexokinase II, glut1 and [18F]-FDG incorporation and changes in 31P-NMR-detectable phosphomonoesters. (Q39239280)

From Wikidata

Jump to navigation Jump to search

scientific article published on 24 November 2012

Language	Label	Description	Also known as
English	Response to trastuzumab by HER2 expressing breast tumour xenografts is accompanied by decreased Hexokinase II, glut1 and [18F]-FDG incorporation and changes in 31P-NMR-detectable phosphomonoesters.	scientific article published on 24 November 2012

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23178956%20AND%20SRC:MED&resulttype=core&format=json

18 February 2020

Response to trastuzumab by HER2 expressing breast tumour xenografts is accompanied by decreased Hexokinase II, glut1 and [18F]-FDG incorporation and changes in 31P-NMR-detectable phosphomonoesters (English)

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23178956%20AND%20SRC:MED&resulttype=core&format=json

18 February 2020

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

tumour xenograft

1 reference

based on heuristic

inferred from title

1

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23178956%20AND%20SRC:MED&resulttype=core&format=json

18 February 2020

author name string

M Virginia C L Appleyard

2

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23178956%20AND%20SRC:MED&resulttype=core&format=json

18 February 2020

Sheila Sharp

3

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23178956%20AND%20SRC:MED&resulttype=core&format=json

18 February 2020

Ian N Fleming

4

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23178956%20AND%20SRC:MED&resulttype=core&format=json

18 February 2020

Karen Murray

5

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23178956%20AND%20SRC:MED&resulttype=core&format=json

18 February 2020

Alastair M Thompson

6

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23178956%20AND%20SRC:MED&resulttype=core&format=json

18 February 2020

language of work or name

1 reference

based on heuristic

inferred from title

publication date

24 November 2012

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23178956%20AND%20SRC:MED&resulttype=core&format=json

18 February 2020

Cancer Chemotherapy and Pharmacology

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23178956%20AND%20SRC:MED&resulttype=core&format=json

18 February 2020

71

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23178956%20AND%20SRC:MED&resulttype=core&format=json

18 February 2020

2

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23178956%20AND%20SRC:MED&resulttype=core&format=json

18 February 2020

473-480

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23178956%20AND%20SRC:MED&resulttype=core&format=json

18 February 2020

Monitoring of early response to neoadjuvant chemotherapy in stage II and III breast cancer by [18F]fluorodeoxyglucose positron emission tomography.

1 reference

https://api.crossref.org/works/10.1007%2FS00280-012-2032-6

21 January 2018

Tumor metabolism and blood flow changes by positron emission tomography: relation to survival in patients treated with neoadjuvant chemotherapy for locally advanced breast cancer

1 reference

https://api.crossref.org/works/10.1007%2FS00280-012-2032-6

21 January 2018

Serial 2-[18F] fluoro-2-deoxy-D-glucose positron emission tomography (FDG-PET) to monitor treatment of bone-dominant metastatic breast cancer predicts time to progression (TTP).

1 reference

https://api.crossref.org/works/10.1007%2FS00280-012-2032-6

21 January 2018

Fibronectin stimulates endothelial cell 18F-FDG uptake through focal adhesion kinase-mediated phosphatidylinositol 3-kinase/Akt signaling

1 reference

https://api.crossref.org/works/10.1007%2FS00280-012-2032-6

21 January 2018

Tumour glycolysis: the many faces of HIF.

1 reference

https://api.crossref.org/works/10.1007%2FS00280-012-2032-6

21 January 2018

Prospective study of positron emission tomography for evaluation of the activity of lapatinib, a dual inhibitor of the ErbB1 and ErbB2 tyrosine kinases, in patients with advanced tumors.

1 reference

https://api.crossref.org/works/10.1007%2FS00280-012-2032-6

21 January 2018

18F-FDG small-animal PET/CT differentiates trastuzumab-responsive from unresponsive human breast cancer xenografts in athymic mice

1 reference

https://api.crossref.org/works/10.1007%2FS00280-012-2032-6

21 January 2018

Imaging biomarkers predict response to anti-HER2 (ErbB2) therapy in preclinical models of breast cancer

1 reference

https://api.crossref.org/works/10.1007%2FS00280-012-2032-6

21 January 2018

Trastuzumab: a review of its use in the management of HER2-positive metastatic and early-stage breast cancer

1 reference

https://api.crossref.org/works/10.1007%2FS00280-012-2032-6

21 January 2018

HER2 assessment on core biopsy specimens using monoclonal antibody CB11 accurately determines HER2 status in breast carcinoma

1 reference

https://api.crossref.org/works/10.1007%2FS00280-012-2032-6

21 January 2018

Evaluation of HER-2/neu oncogene status in breast tumors on tissue microarrays

1 reference

https://api.crossref.org/works/10.1007%2FS00280-012-2032-6

21 January 2018

Quantitative analysis of changes in ER, PR and HER2 expression in primary breast cancer and paired nodal metastases.

1 reference

https://api.crossref.org/works/10.1007%2FS00280-012-2032-6

21 January 2018

Prospective comparison of switches in biomarker status between primary and recurrent breast cancer: the Breast Recurrence In Tissues Study (BRITS).

1 reference

https://api.crossref.org/works/10.1007%2FS00280-012-2032-6

21 January 2018

Systems biology reveals new strategies for personalizing cancer medicine and confirms the role of PTEN in resistance to trastuzumab.

1 reference

https://api.crossref.org/works/10.1007%2FS00280-012-2032-6

21 January 2018

The phosphoinositide 3-kinase inhibitor PI-103 downregulates choline kinase alpha leading to phosphocholine and total choline decrease detected by magnetic resonance spectroscopy.

1 reference

https://api.crossref.org/works/10.1007%2FS00280-012-2032-6

21 January 2018

Magnetic resonance spectroscopy (MRS) in the investigation of cancer at The Royal Marsden Hospital and The Institute of Cancer Research.

1 reference

https://api.crossref.org/works/10.1007%2FS00280-012-2032-6

21 January 2018

Response of choline metabolites to docetaxel therapy is quantified in vivo by localized (31)P MRS of human breast cancer xenografts and in vitro by high-resolution (31)P NMR spectroscopy of cell extracts

1 reference

https://api.crossref.org/works/10.1007%2FS00280-012-2032-6

21 January 2018

Metabolite changes in HT-29 xenograft tumors following HIF-1alpha inhibition with PX-478 as studied by MR spectroscopy in vivo and ex vivo

1 reference

https://api.crossref.org/works/10.1007%2FS00280-012-2032-6

21 January 2018

Magnetic Resonance Spectroscopy of cancer-practicalities of multi-centre trials and early results in non-Hodgkin's lymphoma

1 reference

https://api.crossref.org/works/10.1007%2FS00280-012-2032-6

21 January 2018

Quantitative 31P magnetic resonance spectroscopy of the human breast at 7 T.

1 reference

https://api.crossref.org/works/10.1007%2FS00280-012-2032-6

21 January 2018

A systematic review of PET and PET/CT in oncology: a way to personalize cancer treatment in a cost-effective manner?

1 reference

https://api.crossref.org/works/10.1007%2FS00280-012-2032-6

21 January 2018

Changes in 18F-fluorodeoxyglucose and 18F-fluorodeoxythymidine positron emission tomography imaging in patients with non-small cell lung cancer treated with erlotinib

1 reference

https://api.crossref.org/works/10.1007%2FS00280-012-2032-6

21 January 2018

The rate-limiting step for tumor [18F]fluoro-2-deoxy-D-glucose (FDG) incorporation

1 reference

https://api.crossref.org/works/10.1007%2FS00280-012-2032-6

21 January 2018

Changes in 2-fluoro-2-deoxy-D-glucose incorporation, hexokinase activity and lactate production by breast cancer cells responding to treatment with the anti-HER-2 antibody trastuzumab

1 reference

https://api.crossref.org/works/10.1007%2FS00280-012-2032-6

21 January 2018

Effector and precursor phenotypes of lymphokine-activated killer cells in mice with severe combined immunodeficiency (scid) and athymic (nude) mice.

1 reference

https://api.crossref.org/works/10.1007%2FS00280-012-2032-6

21 January 2018

Trastuzumab causes antibody-dependent cellular cytotoxicity-mediated growth inhibition of submacroscopic JIMT-1 breast cancer xenografts despite intrinsic drug resistance

1 reference

https://api.crossref.org/works/10.1007%2FS00280-012-2032-6

21 January 2018

Glycoengineered Pichia produced anti-HER2 is comparable to trastuzumab in preclinical study.

1 reference

https://api.crossref.org/works/10.1007%2FS00280-012-2032-6

21 January 2018

Identifiers

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q39239280&oldid=2202713106"